- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
BioArctic AB (BIOAb)
The BioArctic share price today is 312.8000, view ST BIOAb stock exchange data. Track the latest BioArctic share price with real-time updates on BIOAb stock performance including market cap, day range, 52-week range and dividend yield. Access BIOAb charts, earnings dates and analyst estimates to support your investment decisions.
312.8000
-1.2000(-0.38%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
308.8000
318.4000
52 wk Range
175.2000
364.4000
BIOAb is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
308.8000318.4000
52 wk Range
175.2000364.4000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.67%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BIOAb Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Neutral
Price Target
301.4000
Downside
-3.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Analyst Ratings
2 Buy
1 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 301.4000
(-3.64% Downside)
Earnings
Latest Release
20-05-2026
EPS / Forecast
2.39 / -0.23
Revenue / Forecast
437.6M / 190.67M
Compare BIOAb to Peers and Sector
Metrics to compare | BIOAb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBIOAbPeersSector | |
|---|---|---|---|---|
P/E Ratio | 130.1x | −4.0x | −0.4x | |
PEG Ratio | −1.70 | −0.15 | 0.00 | |
Price/Book | 12.6x | 5.7x | 2.6x | |
Price / LTM Sales | 24.2x | 140.8x | 3.0x | |
Upside (Analyst Target) | −8.9% | 130.4% | 57.3% | |
Fair Value Upside | Unlock | −0.3% | 8.9% | Unlock |
BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other ALS diseases. In addition, it offers Lecanemab for intravenous treatment. Further, it is developing Lecanemab for Subcutaneous treatment, which is in registration stage; lecanemab, which is in phase 3 clinical trials for presymptomatic treatment; Exidavnemab, which is in phase 2 clinical trials; Lecanemab back-up, BAN2803, ND3014, and BAN2802 that are in preclinical trials; and ND-BT8825, HD-BT4801, GD-BT6822, ND-BT3814, PD-BT2238 which are in research stage. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the BioArctic (BIOAb) Share Price Today?
The BioArctic share price today is 312.8000.
What is the current BioArctic (BIOAb) share price and day range?
As of 24-06-2026, the BioArctic share price is 312.8000, with a previous close of 312.8000. The share price has ranged from 308.8000 to 318.4000 today, while the 52-week range spans from 175.2000 to 364.4000.
What Is the BioArctic Market Cap?
As of today, BioArctic market cap is 27.7500B.
Does BioArctic Pay Dividends? What's The Current Dividend Yield?
The BioArctic dividend yield is 0.67%.
What Is the BioArctic (BIOAb) Share Price Target?
The average 12-month share price target for BioArctic is 301.4000, with a high estimate of 363 and a low estimate of 240. 2 analysts recommend buying, while 1 suggest selling, with an overall rating of Neutral and -3.64% Downside potential.
What Is BioArctic's Earnings Per Share (TTM)?
The BioArctic EPS (TTM) is 2.3991.
When Is the Next BioArctic Earnings Date?
BioArctic will release its next earnings report on 26-08-2026.
From a Technical Analysis Perspective, Is BIOAb a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does BioArctic Trade On?
BioArctic is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for BioArctic?
The stock symbol for BioArctic is "BIOAb."
How Many Times Has BioArctic Stock Split?
BioArctic has split 0 times.
How Many Employees Does BioArctic Have?
BioArctic has 141 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.